Compare FBGL & VVOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FBGL | VVOS |
|---|---|---|
| Founded | 1996 | 2016 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3M | 9.7M |
| IPO Year | N/A | 2020 |
| Metric | FBGL | VVOS |
|---|---|---|
| Price | $0.51 | $0.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $2.75 |
| AVG Volume (30 Days) | 27.3K | ★ 3.9M |
| Earning Date | 05-15-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.76 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $17,443,000.00 |
| Revenue This Year | N/A | $69.66 |
| Revenue Next Year | N/A | $48.38 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 16.05 |
| 52 Week Low | $0.34 | $0.38 |
| 52 Week High | $1.40 | $7.40 |
| Indicator | FBGL | VVOS |
|---|---|---|
| Relative Strength Index (RSI) | 40.18 | 38.73 |
| Support Level | $0.42 | $0.38 |
| Resistance Level | $0.66 | $0.76 |
| Average True Range (ATR) | 0.04 | 0.07 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 8.08 | 30.17 |
FBS Global Ltd is a green building contractor and an established interior fit-out specialist in institutional, residential, commercial, and industrial building projects. As a green contractor focused on environmentally sound practices, the company aims to bid tenders for green building projects, use green construction methods and green materials for construction projects, including design, supply and installation of ceilings, partitions, timber deck, carpet, acoustic wall paneling, built-in furniture as well as mechanical and electrical services of a building. The company's revenue is derived mainly from the construction contracts and Sales of construction materials.
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.